Personalized medicine and the practice of medicine in the 21st century

McGill Journal of Medicine

Volumn 10, Issue 1, 2007, Pages 53-57

  Issa, Amalia M ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTICONVULSIVE AGENT; ATOMOXETINE; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CODEINE; FLUOROURACIL; FLUOXETINE; GLIPIZIDE; HYDRALAZINE; IMATINIB; IRINOTECAN; ISONIAZID; LOSARTAN; MERCAPTOPURINE; PACLITAXEL; PHENYTOIN; PROCAINAMIDE; RITUXIMAB; SULFONAMIDE; THIORIDAZINE; TIOGUANINE; TOLBUTAMIDE; TRASTUZUMAB; WARFARIN;

BREAST CANCER; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG SYNTHESIS; FAMILY HISTORY; GENOTYPE; HEALTH CARE; HEALTH CARE SYSTEM; HUMAN; MEDICAL PRACTICE; PHARMACOGENETICS; PHARMACOGENOMICS; QUALITY CONTROL; REIMBURSEMENT; REVIEW;

EID: 34047238164     PISSN: 1201026X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Garrod AE. The Incidence of Alkaptonuria: a study in Chemical Individuality. Lancet 1902; 2:1616-1620.
2. Carsen PE, Flanagan CL, Iokes CE, Alving AS. Enzymatic Deficiency in Primaquine-sensitive Erythrocytes. Science 1956; 124:484-485.
3. Kalow W and Gunn DR. The Relation Between Dose of Succinylcholine and Duration of Apnea in Man. J. Pharmacol. Exp. Therapeutics 1957; 120(2):203-14.
4. Issa AM. Ethical Perspectives on Pharmacogenomic Profiling in the Drug Development Process. Nat Rev Drug Discovery 2002; 1:300-308.
5. Evans WE and Relling MV. Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics. Science 1999; 286:487-491.
6. Arledge T, Freeman A, Arbuckle J, Mosteller M, Manasco P. Applications of Pharmacogenetics to Drug Development: the Glaxo Wellcome Experience. Drug Metab. Rev. 2000; 32:387-394.
7. Kurth JH. Pharmacogenomics: Future Promise of a Tool for Identifying Patients at Risk. Drug Info J. 2000; 34:223-227.
8. ClinicalTrials.gov. Bethesda MD: National Library of Medicine. Available at: http://clinicaltrials.gov. Accessed: October 3, 2006.
9. Albanell J and Baselga J. Trastuzumab, A humanized anti-HER 2 monoclonal antibody, for the treatment of breast cancer. Drugs Today 1999; 35:931-946.
10. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and Safety of Trastuzumab as a Single Agent in First-line Treatment of HER 2-Overexpressing Metastatic Breast Cancer. J. Clin. Oncol. 2002; 20:719-726.
11. Food and Drug Administration. Letter of Approval. Available at: www.fda.gov/cder/approval/index. Accessed October 26, 2006.
12. Henry CM. Pharmacogenomics. Chemical and Engineering News. 2001; 79(33):37-42. Available at: http://pubs.acs.org/ cen/coverstory/7933/ 7933pharmacogenomics.html. Accessed: October 26, 2006.
13. Hamilton DP. Genentech's Profit Jumps 64% on Strong Cancer-Drug Sales. Wall Street Journal (Eastern edition). January 11, 2006.
14. Cohen MH, Moses ML, Pazdur R. Gleevec for the Treatment of Chronic Myelogenous Leukemia: US Food and Drug Administration Regulatory Mechanisms, Accelerated Approval, and Orphan Drug Status. Oncologist 2002; 7:390-392.
15. Deininger MW. Basic Science Going Clinical: Molecularly Targeted Therapy of Chronic Myelogenous Leukemia. J Cancer Res Clin Oncol. 2004; 130:59-72.
16. Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: Ongoing and Future Clinical Development. Seminars in Oncology 2002; 29:105-12.
17. Ross J, Gray K, Schenkein D, et al. Antibody-based Therapeutics in Oncology. Exp. Rev. Anticancer Therapy 2003; 3:107-21.
18. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R. Influence of CYP2C9 and CYP2C19 Genetic Polymorphisms on Warfarin Maintenance Dose and Metabolic Clearance. Clin. Pharmacol. Therap. 2002; 72(6):702-710.
19. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose. N. Engl. J. Med. 2005; 352(22): 2285-2293.
20. Aquilante CL, Langaee TY, Lopez LM, et al. Influence of Coagulation Factor, Vitamin K Epoxide Reductase Complex Subunit 1, and Cytochrome P450 2C9 Gene Polymorphisms on Warfarin Dose Requirements. Clin. Pharmacol. Therap. 2006; 79(4):291-302.
21. Food and Drug Administration, Summary Minutes of the Clinical Pharmacology Subcommittee Meeting of the Advisory Committee for Pharmaceutical Science, November 14-15, 2005.
22. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic Review. JAMA 2001; 286(18):2270-2279.
23. European Society of Human Genetics. Polymorphic Sequence Variants in Medicine: Technical, Social, Legal and Ethical issues Pharmacogenomics as an Example, Background Document Available at: http://www.eshg.org/ESHG-IPTSPGX.pdf. Accessed: October 25, 2006.
24. Burrill & Company. The Burrill Personalized Medicine Report. San Francisco: Burrill Media Group; 2005.
25. Blue Cross Blue Shield. Special Report: Genotyping for Cytochrome P450 Polymorphisms to Determine Drug Metabolizer Status. Technology Evaluation Center Assessment Program 2006; 19(9). Available at: http://www.bcbs.com/tec/ Vol19/19_09.pdf. Accessed: October 25, 2006.
26. Committee on Quality of Health Care in America. Crossing the Quality Chasm: a New Health System for the 21st Century. Washington, DC: National Academy Press; 2001.
27. The ecade of health information technology: delivering consumer-centric and information-rich health care. US Dept of Health and human Services Web site. Available at: http://www.hhs.gov/onchit/framework/hitframework.pdf. Accessed October 3, 2006.
28. Issa AM. Pharmacogenomic Profiling in post-marketing surveillance: Prospects and Challenges Pharmacogenomics 4:647-655; 2003.
29. Phillips KA, Van Bebber SL. Cost-effectiveness of pharmacogenomic interventions: A systematic review of the literature. Pharmacogenomics 5(8):1139-1149; 2004.
30. Issa AM. Ethical considerations in clinical pharmacogenomics research. Trends Pharmacol. Sci. 21:247-250; 2000.